RxDoctor Payments Data

Robert Larimer, MD

Family Medicine · Alexandria, LANPI 1023052024

Payments from drug & device makers

$1,798in general payments, 2019–2025

Across 54 payments — averaging $33.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$250
  • Vanda Pharmaceuticals Inc.$242
  • Teva Pharmaceuticals USA, Inc.$194
  • Ardelyx, Inc.$177
  • UCB, Inc.$167
  • Esperion Therapeutics, Inc.$125
  • plus $642 from 15 others

What the payments were for

  • Food & beverage$1,798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,798 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,329
Medicare patients
53
Services billed
136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)22$188,681
SprycelDasatinib12$128,321
AubagioTeriflunomide11$89,789
ProliaDenosumab28$52,471
AptiomEslicarbazepine Acetate25$33,904
XcopriCenobamate17$26,386
FycompaPerampanel20$25,902
Aripiprazole59$15,481
Pantoprazole Sodium71$14,854
Budesonide27$13,904
ArexvyRsvpref3 Antigen/As01e/Pf44$13,332
EliquisApixaban20$12,804
FarxigaDapagliflozin Propanediol18$11,603
NayzilamMidazolam15$10,567
Combivent RespimatIpratropium/Albuterol Sulfate20$10,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$31$33,90425 claims
SK Life Science, Inc.Xcopri$94$26,38617 claims
Eisai Inc.Fycompa$14$25,90220 claims
UCB, Inc.Nayzilam$167$10,56715 claims
Johnson & JohnsonInvokana$44$8,23413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →